Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma

NCT01701076 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Cantonal Hospital of St. Gallen

Collaborators